The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 3.81 — safe zoneOK
- Earnings-manipulation signal · Beneish M -1.84 — no flag raisedOK
- Earnings quality 62/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as ELI LILLY & Co reports it. History and quarterly detail are in the app.
- Net product revenue$61.0B
- Cardiometabolic Health$48.2B
- Oncology$9.4B
- Immunology$5.2B
- Collaboration and Other Revenue$4.2B
Leadership changes
From ELI LILLY & Co's own filings, the day they're filed.
- Karen Walker · Chief Executive Officer · departureeff. 2024-12-01
- Gordon Brooks · chief financial officer · appointmenteff. 2024-07-15
- Anat Ashkenazi · chief financial officer · departureeff. 2024-07-15
Latest filings
- 8-K · Company announcement2026-05-20
- 8-K · Company announcement2026-05-07
- 10-Q · Quarterly report2026-04-30
- 8-K · Company announcement2026-04-30
- DEF 14A · Annual proxy (pay & governance)2026-03-20
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about ELI LILLY & Co, every answer cited🔒
- The Intelligence Brief — added when ELI LILLY & Co's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.